Synthaverse S.A. - Asset Resilience Ratio
Synthaverse S.A. (SVE) has an Asset Resilience Ratio of 0.02% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Synthaverse S.A. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Synthaverse S.A.'s Asset Resilience Ratio has changed over time. See SVE total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Synthaverse S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SVE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł55.00K | 0.02% |
| Total Liquid Assets | zł55.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Synthaverse S.A. maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Synthaverse S.A. Industry Peers by Asset Resilience Ratio
Compare Synthaverse S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Synthaverse S.A. (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Synthaverse S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.02% | zł56.00K ≈ $15.41K |
zł265.90 Million ≈ $73.18 Million |
-4.41pp |
| 2021-12-31 | 4.43% | zł5.17 Million ≈ $1.42 Million |
zł116.83 Million ≈ $32.15 Million |
+4.55pp |
| 2017-12-31 | -0.12% | zł-147.00K ≈ $-40.46K |
zł121.03 Million ≈ $33.31 Million |
-5.17pp |
| 2016-12-31 | 5.04% | zł5.68 Million ≈ $1.56 Million |
zł112.66 Million ≈ $31.00 Million |
+1.62pp |
| 2015-12-31 | 3.42% | zł5.68 Million ≈ $1.56 Million |
zł166.16 Million ≈ $45.73 Million |
+3.36pp |
| 2014-12-31 | 0.06% | zł67.70K ≈ $18.63K |
zł112.33 Million ≈ $30.91 Million |
-- |
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more